Insider Transactions in Q3 2021 at Dexcom Inc (DXCM)
Insider Transaction List (Q3 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
6,743
-1.88%
|
$3,863,739
$573.12 P/Share
|
|
Sep 15
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
6,000
-0.75%
|
$3,240,000
$540.28 P/Share
|
|
Sep 13
2021
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
156
-1.58%
|
$84,396
$541.47 P/Share
|
|
Sep 10
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
626
-5.42%
|
$349,308
$558.33 P/Share
|
|
Sep 10
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
681
-4.97%
|
$379,998
$558.33 P/Share
|
|
Sep 10
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,519
-7.3%
|
$847,602
$558.33 P/Share
|
|
Sep 09
2021
|
Donald Abbey EVP Global Business Services I |
SELL
Open market or private sale
|
Direct |
1,263
-1.26%
|
$683,283
$541.68 P/Share
|
|
Sep 09
2021
|
Paul R Flynn EVP Global Revenue |
SELL
Open market or private sale
|
Direct |
752
-3.06%
|
$406,832
$541.56 P/Share
|
|
Sep 09
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,263
-0.89%
|
$683,283
$541.7 P/Share
|
|
Sep 09
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
987
-2.86%
|
$533,967
$541.56 P/Share
|
|
Sep 09
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,263
-1.29%
|
$683,283
$541.68 P/Share
|
|
Sep 09
2021
|
Chad Patterson EVP Global Marketing |
SELL
Open market or private sale
|
Direct |
291
-1.43%
|
$157,431
$541.69 P/Share
|
|
Sep 09
2021
|
Kevin R Sayer President CEO and Chairman |
SELL
Open market or private sale
|
Direct |
3,017
-1.43%
|
$1,632,197
$541.32 P/Share
|
|
Sep 09
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
407
-1.61%
|
$220,187
$541.91 P/Share
|
|
Sep 09
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
407
-1.46%
|
$220,187
$541.56 P/Share
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
5,597
-5.27%
|
$3,050,365
$545.78 P/Share
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
BUY
Other acquisition or disposition
|
Indirect |
2,498
+15.96%
|
-
|
|
Sep 09
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Other acquisition or disposition
|
Direct |
2,498
-15.09%
|
-
|
|
Sep 09
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Open market or private sale
|
Direct |
2,223
-1.65%
|
$1,211,535
$545.69 P/Share
|
|
Sep 09
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
9,462
-3.29%
|
$5,156,790
$545.76 P/Share
|
|
Sep 08
2021
|
Quentin S. Blackford Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
7,681
-10.14%
|
$4,193,826
$546.09 P/Share
|
|
Sep 07
2021
|
Jereme M Sylvain EVP, Chief Financal Officer |
SELL
Open market or private sale
|
Direct |
587
-4.04%
|
$319,915
$545.41 P/Share
|
|
Aug 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.82%
|
$258,500
$517.24 P/Share
|
|
Aug 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,078
-0.54%
|
$555,170
$515.67 P/Share
|
|
Aug 11
2021
|
Karen M Dahut Director |
BUY
Other acquisition or disposition
|
Indirect |
387
+50.0%
|
-
|
|
Aug 11
2021
|
Karen M Dahut Director |
SELL
Other acquisition or disposition
|
Direct |
387
-18.62%
|
-
|
|
Aug 04
2021
|
Shelly Ramasamy Selvaraj SVP Chief Information Officer |
SELL
Bona fide gift
|
Direct |
250
-1.55%
|
-
|
|
Aug 03
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
2,757
-2.83%
|
$1,422,612
$516.06 P/Share
|
|
Jul 30
2021
|
Jacob Steven Leach EVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
12,087
-14.63%
|
$5,753,412
$476.7 P/Share
|
|
Jul 26
2021
|
Patrick Michael Murphy EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
500
-2.74%
|
$229,000
$458.79 P/Share
|
|
Jul 23
2021
|
Steven Robert Pacelli EVP Managing Director Dexcom V |
SELL
Open market or private sale
|
Direct |
1,079
-1.06%
|
$486,629
$451.74 P/Share
|
|
Jul 16
2021
|
Sumi Shrishrimal SVP Chief Risk Officer |
SELL
Open market or private sale
|
Direct |
400
-3.08%
|
$180,000
$450.0 P/Share
|
|
Jul 06
2021
|
Andrew K Balo EVP Regulatory Strategy Clinic |
SELL
Open market or private sale
|
Indirect |
2,974
-4.81%
|
$1,278,820
$430.11 P/Share
|